WG
PSTX

Winton Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Winton Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,577
Closed -$25.2K – 880
2023
Q3 		$25.2K Sell
10,577
-253
-2% -$530 ﹤0.01% 754
2023
Q2 		$19.1K Buy
+10,830
New +$27.7K ﹤0.01% 745

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Winton Group's PSTX Position: Q4 2023 in Review

Winton Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2023, closing a stake of 10,577 shares — an estimated $25.2K sold.

Winton Group first reported a position in PSTX in Q2 2023 and held it in 2 quarters. The position peaked at $25.2K in Q3 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q4 2023.

  • Winton Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Winton Group sold 10,577 Poseida Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $25.2K.
  • Winton Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Winton Group's Poseida Therapeutics, Inc. Common Stock position peaked at $25.2K in Q3 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Winton Group's 13F filing for Q4 2023, filed 12 Feb 2024.